LLY

1,006.06

+1.27%↑

JNJ

209.91

+1.6%↑

ABBV

223.8

-0.55%↓

UNH

336.55

+2.68%↑

AZN

90.26

-1.28%↓

LLY

1,006.06

+1.27%↑

JNJ

209.91

+1.6%↑

ABBV

223.8

-0.55%↓

UNH

336.55

+2.68%↑

AZN

90.26

-1.28%↓

LLY

1,006.06

+1.27%↑

JNJ

209.91

+1.6%↑

ABBV

223.8

-0.55%↓

UNH

336.55

+2.68%↑

AZN

90.26

-1.28%↓

LLY

1,006.06

+1.27%↑

JNJ

209.91

+1.6%↑

ABBV

223.8

-0.55%↓

UNH

336.55

+2.68%↑

AZN

90.26

-1.28%↓

LLY

1,006.06

+1.27%↑

JNJ

209.91

+1.6%↑

ABBV

223.8

-0.55%↓

UNH

336.55

+2.68%↑

AZN

90.26

-1.28%↓

Начало・Списък с акции・Collegium Pharmaceutical Inc

C
Collegium Pharmaceutical Inc

Затворен

СекторЗдравеопазване

48.36 -0.49

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

47.97

Максимум

49.01

Ключови измерители
By Trading Economics
Приходи	20M 32M
Продажби	21M 209M
P/E Средно за сектора	29.393 77.671
Марж на печалбата	15.049
Служители	357
EBITDA	28M 122M

Препоръки
By TipRanks
Препоръки	Силна покупка
12-месечна прогноза	+2.33% upside

Пазарни показатели
By TradingEconomics
Пазарна капитализация	377M 1.5B
Предишно отваряне	48.85
Предишно затваряне	48.36

Настроения в новините

By Acuity

24%

76%

75 / 374 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Bullish Evidence

27.09 / 27.6 Подкрепа & съпротива

Collegium Pharmaceutical Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

10.12.2025 г., 22:02 ч. UTC

Печалби

Synopsys Sees Strong 2026 as Ansys Acquisition Boosts 4Q Revenue

10.12.2025 г., 21:46 ч. UTC

Печалби

Adobe Expects Double-Digit Recurring Revenue Growth Next Year

10.12.2025 г., 23:52 ч. UTC

Придобивния, сливания и поглъщания

Paramount Sends Letter to Warner Bros. Shareholders Saying Its Offer Is 'Superior' -- Barrons.com

10.12.2025 г., 23:43 ч. UTC

Пазарно говорене

Nikkei May Rise After Fed Rate Cut -- Market Talk

10.12.2025 г., 23:36 ч. UTC

Пазарно говорене

Gold Consolidates as Traders Digest FOMC Decision -- Market Talk

10.12.2025 г., 23:20 ч. UTC

Печалби

Oracle Reports $16.1 Billion in Revenue, Narrowly Missing Forecasts -- 2nd Update

10.12.2025 г., 23:15 ч. UTC

Печалби

Synopsys Targets Double-Digit Growth Following Ansys Acquisition -- Interview

10.12.2025 г., 22:59 ч. UTC

Пазарно говорене

Печалби

Придобивния, сливания и поглъщания

Adobe Expects Semrush Deal to Bring in New Users -- Market Talk

10.12.2025 г., 22:45 ч. UTC

Пазарно говорене

Coca-Cola's New CEO Pick Looks A Lot Like The Last One -- Market Talk

10.12.2025 г., 22:40 ч. UTC

Печалби

Synopsys Stock Rises on Earnings Beat, Higher Guidance -- Barrons.com

10.12.2025 г., 22:06 ч. UTC

Придобивния, сливания и поглъщания

Paramount Sends Letter to Warner Bros. Shareholders Saying Their Offer Is 'Superior' -- Barrons.com

10.12.2025 г., 22:06 ч. UTC

Печалби

Oracle Reports Mixed Earnings. The Stock Is Falling. -- Barrons.com

10.12.2025 г., 22:02 ч. UTC

Печалби

Synopsys Stock Rises on Earnings Beat, Higher Guidance -- Barrons.com

10.12.2025 г., 22:00 ч. UTC

Печалби

Oracle Reports $16.1 Billion in Revenue, Narrowly Missing Forecasts -- Update

10.12.2025 г., 21:53 ч. UTC

Печалби

Adobe Earnings Show 'Rapid Adoption' of AI Tools. The Stock Is Up. -- Barrons.com

10.12.2025 г., 21:50 ч. UTC

Придобивния, сливания и поглъщания

Investors Bet That a Higher Bid for Warner Is Coming -- Update

10.12.2025 г., 21:50 ч. UTC

Пазарно говорене

Печалби

Придобивния, сливания и поглъщания

Financial Services Roundup: Market Talk

10.12.2025 г., 21:50 ч. UTC

Пазарно говорене

Health Care Roundup: Market Talk

10.12.2025 г., 21:50 ч. UTC

Пазарно говорене

Auto & Transport Roundup: Market Talk

10.12.2025 г., 21:45 ч. UTC

Придобивния, сливания и поглъщания

Paramount Sends Letter to Warner Bros. Shareholders Saying Their Offer Is 'Superior' -- Barrons.com

10.12.2025 г., 21:33 ч. UTC

Печалби

Oracle Reports $16.1 Billion in Revenue, Narrowly Missing Forecasts -- WSJ

10.12.2025 г., 21:32 ч. UTC

Печалби

Oracle Reports Mixed Earnings. The Stock Is Falling. -- Barrons.com

10.12.2025 г., 21:28 ч. UTC

Придобивния, сливания и поглъщания

Sverica Capital Management Announces Sale of Coastal Cloud Holdings to Tata Consultancy Services for $700M

10.12.2025 г., 21:25 ч. UTC

Печалби

Adobe Earnings Show 'Rapid Adoption' of AI Tools. The Stock Is Up. -- Barrons.com

10.12.2025 г., 21:18 ч. UTC

Придобивния, сливания и поглъщания

Paramount Skydance: Company Has Air Tight Financing to Deliver on Warner Bros. Offer >PSKY

10.12.2025 г., 21:16 ч. UTC

Печалби

Oracle Reports Mixed Earnings. The Stock is Falling. -- Barrons.com

10.12.2025 г., 21:15 ч. UTC

Придобивния, сливания и поглъщания

Paramount Skydance: Public Offer for Warner Bros. Delivers Superior Value, Faster, More Certain Path to Completion

10.12.2025 г., 21:15 ч. UTC

Печалби

Oracle: 'Sold Ampere Because We No Longer Think It Is Strategic for Us to Continue Designing, Manufacturing and Using Our Own Chips in Our Cloud Datacenters' >ORCL

10.12.2025 г., 21:14 ч. UTC

Печалби

Oracle 2Q Non-GAAP Operating Income Was $6.7 B >ORCL

10.12.2025 г., 21:14 ч. UTC

Печалби

Oracle 2Q GAAP Operating Income Was $4.7 B >ORCL

Сравнение с други в отрасъла

Ценова промяна

Collegium Pharmaceutical Inc Прогноза

Ценова цел

By TipRanks

2.33% нагоре

12-месечна прогноза

Среден 50 USD 2.33%

Висок 58 USD

Нисък 46 USD

Според 4 анализатори от Wall Street, предложили 12-месечна ценова цел за Collegium Pharmaceutical Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

4 ratings

Купи

Задържане

Продай

Според 4 анализатори, дали борсови рейтинги на Collegium Pharmaceutical Inc през последните 3 месеца.

Техническа оценка

By Trading Central

27.09 / 27.6Подкрепа & съпротива

Bullish events outweigh bearish events.

The bullish and bearish events are balanced.

All events are bearish.

Настроение

By Acuity

75 / 374 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Collegium Pharmaceutical Inc

Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain. The company was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. Collegium Pharmaceutical, Inc. was incorporated in 2002 and is headquartered in Stoughton, Massachusetts.